Literature DB >> 32564907

Pathological fracture does not affect prognosis in dedifferentiated chondrosarcoma of the limbs.

Andrea Sambri1, Gianmarco Tuzzato2, Davide Maria Donati3, Massimiliano De Paolis4, Giuseppe Bianchi2.   

Abstract

BACKGROUND: The aim of this retrospective study is to analyze history and treatment outcomes of pathological fracture (PF) in dedifferentiated chondrosarcoma (DdChS) of the limbs..
METHODS: We retrospectively reviewed 175 adult patients with primary DdChS of the limbs.Disease-specific survival (OS) and local recurrence (LR) were analyzed.
RESULTS: Median age was 66 years (range, 29-91). Most DdChS (121, 69.1%) were localized in the femur. Forty-nine (28.0%) had metastasis at diagnosis; thirty-nine DdChS (22.3%) had a PF.OS rate was lower in patients with metastasis at diagnosis (8.6% Vs 41.0% at 10 years, p < 0.001). A similar OS was observed among patients with localized disease, whether with/without PF (p = 0.638), with/without chemotherapy (p = 0.543) and independently from the type of surgery (resection/amputation) (p = 0.877). Amputation reduces the risk of LR (80.0% vs 63.1% at 5 years, p = 0.039), particularly in the PF group..
CONCLUSION: Patients with metastases have a particularly poor prognosis in DdChS, but pathological fracture does not influence prognosis in terms of survival and local control. Initial curative resection is essential in order to reduce the chance of recurrences. Amputation might be an option in patients with localized disease and a PF to reduce the risk of LR..
Copyright © 2020 The Japanese Orthopaedic Association. Published by Elsevier B.V. All rights reserved.

Entities:  

Year:  2020        PMID: 32564907     DOI: 10.1016/j.jos.2020.04.013

Source DB:  PubMed          Journal:  J Orthop Sci        ISSN: 0949-2658            Impact factor:   1.601


  3 in total

Review 1.  Dedifferentiated Chondrosarcoma: A Case Series and Review of the Literature.

Authors:  Charles A Gusho; Linus Lee; Athan Zavras; Zachary Seikel; Ira Miller; Matthew W Colman; Steven Gitelis; Alan T Blank
Journal:  Orthop Rev (Pavia)       Date:  2022-05-31

2.  Clinical features and treatment outcomes of dedifferentiated and grade 3 chondrosarcoma: A multi-institutional study.

Authors:  Eiji Kozawa; Yoshihiro Nishida; Akira Kawai; Keiko Hayakawa; Nokitaka Setsu; Hiroyuki Kawashima; Shintaro Iwata; Hiroyuki Tsuchiya; Satoshi Tsukushi; Satoshi Takenaka; Jungo Imanishi; Ichiro Baba; Akihito Nagano; Takeshi Morii; Toshiharu Shirai; Koki Shimizu; Hirotaka Kawano
Journal:  Cancer Sci       Date:  2022-05-18       Impact factor: 6.518

3.  Periostin is a novel histological biomarker for the diagnosis of chondroid tumor.

Authors:  Dough Kim; Ji Yun Jeong; Man-Hoon Han; Jongmin Chae; Ilhyung Park; Jongphil Yoon; Heesoo Kyung; Ha-Jeong Kim; Wonju Jeong
Journal:  Transl Cancer Res       Date:  2021-01       Impact factor: 1.241

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.